JP2022116278A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022116278A5 JP2022116278A5 JP2022090079A JP2022090079A JP2022116278A5 JP 2022116278 A5 JP2022116278 A5 JP 2022116278A5 JP 2022090079 A JP2022090079 A JP 2022090079A JP 2022090079 A JP2022090079 A JP 2022090079A JP 2022116278 A5 JP2022116278 A5 JP 2022116278A5
- Authority
- JP
- Japan
- Prior art keywords
- valsartan
- sacubitril
- molar ratio
- use according
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 25
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 25
- 229960004699 valsartan Drugs 0.000 description 25
- PYNXFZCZUAOOQC-UTKZUKDTSA-N sacubitril Chemical compound C1=CC(C[C@H](C[C@@H](C)C(=O)OCC)NC(=O)CCC(O)=O)=CC=C1C1=CC=CC=C1 PYNXFZCZUAOOQC-UTKZUKDTSA-N 0.000 description 23
- 229960003953 sacubitril Drugs 0.000 description 23
- 206010007556 Cardiac failure acute Diseases 0.000 description 7
- 238000001990 intravenous administration Methods 0.000 description 5
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 4
- 102400001263 NT-proBNP Human genes 0.000 description 4
- 108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 3
- 208000038002 heart failure with reduced ejection fraction Diseases 0.000 description 3
- 239000002934 diuretic Substances 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 208000028185 Angioedema Diseases 0.000 description 1
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000002682 Hyperkalemia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 239000002170 aldosterone antagonist Substances 0.000 description 1
- 229940083712 aldosterone antagonist Drugs 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 239000004041 inotropic agent Substances 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- SOBHUZYZLFQYFK-UHFFFAOYSA-K trisodium;hydroxy-[[phosphonatomethyl(phosphonomethyl)amino]methyl]phosphinate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)CN(CP(O)([O-])=O)CP([O-])([O-])=O SOBHUZYZLFQYFK-UHFFFAOYSA-K 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18190588 | 2018-08-23 | ||
| EP18190588.6 | 2018-08-23 | ||
| EP18199733 | 2018-10-10 | ||
| EP18199733.9 | 2018-10-10 | ||
| JP2021507507A JP2021525791A (ja) | 2018-08-23 | 2019-08-22 | 新たな心不全治療用医薬の使用 |
| PCT/IB2019/057081 WO2020039386A1 (en) | 2018-08-23 | 2019-08-22 | New pharmaceutical use for the treatment of heart failure |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021507507A Division JP2021525791A (ja) | 2018-08-23 | 2019-08-22 | 新たな心不全治療用医薬の使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022116278A JP2022116278A (ja) | 2022-08-09 |
| JP2022116278A5 true JP2022116278A5 (cg-RX-API-DMAC10.html) | 2022-08-26 |
Family
ID=68069829
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021507507A Pending JP2021525791A (ja) | 2018-08-23 | 2019-08-22 | 新たな心不全治療用医薬の使用 |
| JP2022090079A Pending JP2022116278A (ja) | 2018-08-23 | 2022-06-02 | 新たな心不全治療用医薬の使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021507507A Pending JP2021525791A (ja) | 2018-08-23 | 2019-08-22 | 新たな心不全治療用医薬の使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20210177803A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3840746A1 (cg-RX-API-DMAC10.html) |
| JP (2) | JP2021525791A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20210032437A (cg-RX-API-DMAC10.html) |
| CA (1) | CA3110152A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2020039386A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240173982A (ko) | 2023-06-07 | 2024-12-16 | 인제대학교 산학협력단 | 세레블론 단백질 또는 상기 단백질을 코딩하는 유전자를 유효성분으로 포함하는 심부전 진단용 바이오마커 조성물 및 치료용 약학 조성물 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0443983B1 (de) | 1990-02-19 | 1996-02-28 | Ciba-Geigy Ag | Acylverbindungen |
| US5217996A (en) | 1992-01-22 | 1993-06-08 | Ciba-Geigy Corporation | Biaryl substituted 4-amino-butyric acid amides |
| DE60315795T2 (de) | 2002-01-17 | 2008-06-05 | Novartis Ag | Pharmazeutische zusammensetzung enthaltend valsartan und nep-inhibitoren |
| AR057882A1 (es) | 2005-11-09 | 2007-12-26 | Novartis Ag | Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra |
| KR101589317B1 (ko) | 2007-11-06 | 2016-01-28 | 노파르티스 아게 | 안지오텐신 수용체 길항제/차단제 （ａｒｂ） 및 중성 엔도펩티다제 （ｎｅｐ） 억제제의 초구조에 기초한 이중-작용 제약 조성물 |
| CN103079554A (zh) | 2010-08-24 | 2013-05-01 | 诺华有限公司 | 在接受抗凝血剂疗法的哺乳动物中治疗高血压和/或预防或治疗心力衰竭 |
| RU2667643C2 (ru) | 2012-08-24 | 2018-09-21 | Новартис Аг | Ингибиторы nep для лечения заболеваний, характеризующихся увеличением или ремоделированием предсердия |
| CN105102440A (zh) | 2012-10-16 | 2015-11-25 | 埃克斯福科技公司 | 单醣至5-(氯甲基)-2-呋喃甲醛的有效、高产率转化 |
| DK3626270T3 (da) | 2013-08-26 | 2024-01-15 | Novartis Ag | Behandling af kardiovaskulære sygdomme |
| EP3038653A1 (en) | 2013-08-26 | 2016-07-06 | Novartis AG | New use |
| CN106414416B (zh) | 2014-09-09 | 2020-03-27 | 上海翰森生物医药科技有限公司 | 结晶型ARB-NEPi复合物及其制备方法和应用 |
| CN105461647B (zh) | 2014-09-28 | 2018-06-29 | 四川海思科制药有限公司 | 缬沙坦沙库比曲三钠盐复合物的固态形式及其制备方法和用途 |
| CN105503760A (zh) | 2014-10-10 | 2016-04-20 | 上海翰森生物医药科技有限公司 | 结晶型ARB-NEPi双阳离子复合物及其制备方法和应用 |
| DK3229799T3 (en) | 2014-12-08 | 2019-02-11 | Crystal Pharmatech Co Ltd | CRYSTALLINIC FORMS OF SUPRAMOLECULATED TRINATRIUM COMPLEX, INCLUDING VALSARTAN AND AHU-377, AND PROCEDURES THEREOF |
| WO2016051393A2 (en) | 2014-12-26 | 2016-04-07 | Crystal Pharmatech Inc. | Crystalline form iv of trisodium supramolecular complex comprising valsartan and ahu-377 and methods thereof |
| US10562866B2 (en) | 2015-02-06 | 2020-02-18 | Mylan Laboratories Limited | Amorphous trisodium sacubitril valsartan and a process for the preparation thereof |
| CN106032361A (zh) | 2015-03-11 | 2016-10-19 | 齐鲁制药有限公司 | Lcz-696的新晶型及其制备方法 |
| WO2016151525A1 (en) | 2015-03-26 | 2016-09-29 | Dr. Reddy’S Laboratories Limited | Crystalline form of lcz-696 |
| PL4212152T3 (pl) * | 2015-05-11 | 2025-08-11 | Novartis Ag | Schemat dawkowania sakubitrylu-walsartanu do leczenia przewlekłej skurczowej niewydolności serca |
| WO2016193883A1 (en) | 2015-05-29 | 2016-12-08 | Novartis Ag | Sacubitril and valsartan for treating metabolic disease |
| EP3828175A1 (en) | 2015-06-12 | 2021-06-02 | Teva Pharmaceuticals International GmbH | Solid state forms of trisodium valsartan: sacubitril |
| CN106316973A (zh) | 2015-07-07 | 2017-01-11 | 江苏柯菲平医药股份有限公司 | 血管紧张素受体拮抗剂和nep抑制剂药物晶型及其制备 |
| WO2017006254A1 (en) | 2015-07-08 | 2017-01-12 | Novartis Ag | Drug combination comprising an angiotensin ii receptor antagonist, a neutral endopeptidase inhibitor and a mineralcorticoid receptor antagonist |
| WO2017009784A1 (en) | 2015-07-14 | 2017-01-19 | Cadila Healthcare Limited | Solid state forms of trisodium salt of valsartan/sacubitril complex and sacubitril |
| CN105037289B (zh) | 2015-07-17 | 2017-08-22 | 华东理工大学 | 血管紧张素受体拮抗剂和中性内肽酶抑制剂超分子复合体的新晶型 |
| EP3117823A1 (en) | 2015-07-17 | 2017-01-18 | Quimica Sintetica, S.A. | Amorphous solid dispersion comprising an angiotensin receptor blocker and a neutral endopeptidase inhibitor |
| AU2016314543B2 (en) | 2015-08-28 | 2020-07-16 | Hetero Labs Ltd. | Process for the preparation of a dual-acting angiotensin receptor-neprilysin inhibitor compound |
| WO2017037596A1 (en) | 2015-08-28 | 2017-03-09 | Dr. Reddy's Laboratories Limited | Amorphous solid dispersion of lcz-696 |
| US10596151B2 (en) | 2015-08-28 | 2020-03-24 | Novartis Ag | Methods and pharmaceutical compositions for reducing arterial stiffness with a combination of a therapeutic agent blocking the angiotensin receptor and a therapeutic agent inhibiting the NEP enzyme |
| WO2017036420A1 (zh) | 2015-09-06 | 2017-03-09 | 常州方楠医药技术有限公司 | 含沙库比曲和缬沙坦的药用组合物及其制备方法 |
| WO2017042700A1 (en) | 2015-09-07 | 2017-03-16 | Sun Pharmaceutical Industries Limited | Solid forms of valsartan and sacubitril |
| CN105669581B (zh) | 2015-11-09 | 2017-03-22 | 成都苑东生物制药股份有限公司 | 一种血管紧张受体拮抗剂和中性内肽酶抑制剂复合物 |
| WO2017085573A1 (en) | 2015-11-20 | 2017-05-26 | Lupin Limited | Amorphous sacubitril-valsartan complex and process for preparation thereof |
| CN106854187B (zh) | 2015-12-08 | 2020-04-14 | 苏州晶云药物科技股份有限公司 | 一种ahu-377和缬沙坦三钠盐共晶水合物晶型ii的制备方法 |
| CN105348209B (zh) | 2015-12-09 | 2017-12-26 | 浙江天宇药业股份有限公司 | 一种抗心衰药lcz696的制备方法 |
| CN105929031B (zh) | 2015-12-18 | 2018-08-21 | 重庆两江药物研发中心有限公司 | 一种血管紧张素受体拮抗剂和nep抑制剂的复合物中杂质的分离方法 |
| JP7156945B2 (ja) * | 2016-02-03 | 2022-10-19 | ノバルティス アーゲー | 有機化合物のガレヌス製剤 |
| CN107033094A (zh) | 2016-02-04 | 2017-08-11 | 南京卡文迪许生物工程技术有限公司 | 一种药物共晶的晶型及其制备方法和组合物 |
| WO2017154017A1 (en) | 2016-03-07 | 2017-09-14 | Msn Laboratories Limited | Process for the preparation of trisodium (4-{[1s,3r)-1-([1,1'-biphenyl]-4-ylmethyl)-4-ethoxy-3-methyl-4-oxobutyl]amino}-4-oxobutanoate)-(n-pentanoyl-n-{[2'-(1h-tetrazol-1-id-5-yl)[1,1'-biphenyl]-4-yl]methyl}- l-valinate) and its polymorphs thereof |
| WO2017191619A2 (en) | 2016-05-06 | 2017-11-09 | Sun Pharmaceutical Industries Limited | A process for the preparation of a salt of sacubitril and valsartan |
| TW201806936A (zh) | 2016-08-24 | 2018-03-01 | 中化合成生技股份有限公司 | 無定形纈沙坦/沙庫比曲三鈉鹽及其製備方法 |
| EP3522886A4 (en) | 2016-10-10 | 2020-02-19 | Laurus Labs Limited | STABLE AMORPHE FORM OF THE SACUBITRIL VALSARTAN TRINATRIUM COMPLEX AND METHOD FOR THE PRODUCTION THEREOF |
| WO2018069937A1 (en) | 2016-10-13 | 2018-04-19 | Mylan Laboratories Limited | Solid dispersions of trisodium sacubitril valsartan and process for the preparation thereof |
| WO2018078592A1 (en) | 2016-10-28 | 2018-05-03 | Biocon Limited | Amorphous trisodium sacubitril valsartan and process for its preparation |
| CN106518709A (zh) | 2016-11-07 | 2017-03-22 | 济南益新医药技术有限公司 | 一种无定形沙库比曲缬沙坦钠盐复合物的制备方法 |
| CN111592500A (zh) | 2017-01-03 | 2020-08-28 | 上海博志研新药物技术有限公司 | ARB-NEPi复合物、晶型、制备方法及应用 |
-
2019
- 2019-08-22 EP EP19778657.7A patent/EP3840746A1/en not_active Withdrawn
- 2019-08-22 JP JP2021507507A patent/JP2021525791A/ja active Pending
- 2019-08-22 US US17/269,310 patent/US20210177803A1/en not_active Abandoned
- 2019-08-22 KR KR1020217004177A patent/KR20210032437A/ko not_active Ceased
- 2019-08-22 WO PCT/IB2019/057081 patent/WO2020039386A1/en not_active Ceased
- 2019-08-22 CA CA3110152A patent/CA3110152A1/en active Pending
-
2022
- 2022-06-02 JP JP2022090079A patent/JP2022116278A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1744739B1 (en) | Use of treprostinil to treat neuropathic diabetic foot ulcers | |
| RU2020109345A (ru) | Применение мавакамтена для лечения гипертрофической кардиомиопатии | |
| Patel et al. | Carotid sinus syncope induced by malignant tumors in the neck: emergence of vasodepressor manifestations following pacemaker therapy | |
| Lloyd et al. | The treatment of recurrent ventricular tachycardia with bilateral cervico-thoracic sympathetic-ganglionectomy: a report of two cases | |
| JP2025515491A5 (cg-RX-API-DMAC10.html) | ||
| US5571789A (en) | Use of urodilatin in pulmonary and bronchial diseases | |
| JP3084059B2 (ja) | 甲状腺ホルモン心臓治療 | |
| WO1996038173A1 (en) | Brain edema inhibitor | |
| JP2025513289A5 (cg-RX-API-DMAC10.html) | ||
| EP0830131A1 (en) | New pharmacological use of aii-receptor antagonists | |
| JP2025503015A5 (cg-RX-API-DMAC10.html) | ||
| CA2483097A1 (en) | Use of xenon for the control of neurological deficits associated with cardiopulmonary bypass | |
| JP2023544620A5 (cg-RX-API-DMAC10.html) | ||
| Sugiura et al. | Successful peritoneal dialysis for the treatment of inotrope-dependent end-stage heart failure | |
| Sandhofer et al. | Severe cardiovascular complication associated with prolonged starvation | |
| Hoffmann et al. | Results of the Austrian celiprolol postmarketing surveillance study | |
| Lai et al. | Hemofiltration in digoxin overdose | |
| Horita et al. | A case of the toxicity of pilsicainide hydrochloride with comparison of the serial serum pilsicainide levels and electrocardiographic findings | |
| Imamura et al. | Two cases of bronchial asthma after treatment with amiodarone | |
| Kazma et al. | MAR Cardiology & Heart Diseases (2025) 4: 4 | |
| RU2133608C1 (ru) | Способ лечения артериальной гипертензии в климактерическом периоде | |
| JP2010248263A (ja) | 塩酸ランジオロールを含有する頻脈性不整脈の治療剤 | |
| CA2387920C (en) | A new use of levosimendan | |
| JP4784037B2 (ja) | 塩酸ランジオロールを含有する頻脈性不整脈の治療剤 | |
| Tomcsányi | Extremely wide QRS complex with VVI pacing. |